Rapidly accelerated development of neutralizing COVID‐19 antibodies by reducing cell line and CMC development timelines-Reference-Cited by-同舟云学术

Rapidly accelerated development of neutralizing COVID‐19 antibodies by reducing cell line and CMC development timelines

Published:2022-12-19 Issue: Volume: Page:
ISSN:0006-3592
Container-title:Biotechnology and Bioengineering
language:en
Short-container-title:Biotech & Bioengineering

Author:

Tan Kee Wee¹,Ji Pengfei¹,Qian Zichen¹,Gao Qiao¹,Wang Shuai¹,Li Qin¹,Gu Mingzhu¹,Zhang Qi¹,Hou Chengjian¹,Huang Yang¹,Lian Dujuan¹,Wang Junghao¹,Zhang Zheng¹,Zhang Sam¹,Wu Jiansheng¹,Zhou Weichang¹

Affiliation:

1. WuXi Biologics, Waigaoqiao Free Trade Zone Shanghai China

Publisher

Wiley

Subject

Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bit.28302

Reference31 articles.

1. Rapid cGMP manufacturing of COVID‐19 monoclonal antibody using stable CHO cell pools

2. Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies

3. Tackling COVID-19 with neutralizing monoclonal antibodies

4. COVID‐19 Biologics Tracker. (2022).The Antibody Society.https://www.antibodysociety.org/covid-19-biologics-tracker/

5. Comparative study of therapeutic antibody candidates derived from mini-pool and clonal cell lines

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cross‐scale Raman in‐line monitoring capability of cell culture process in large‐scale manufacturing;AIChE Journal;2024-09-09

2. Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool;Vaccines;2024-05-21

3. Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening;Viruses;2024-02-22

4. A high‐fidelity, dual site‐specific integration system in CHO cells by a Bxb1 recombinase;Biotechnology Journal;2024-02

5. Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs;Antibody Therapeutics;2024-01